Age: 5.0
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE; HCP called and reported possible inadvertent administrations of MMR-II, VARIVAX, and PROQUAD after a temperature excursion that occurred on 23DEC2024.; This spontaneous report has been received from a nurse and refers to a unknown number of patients of unknown age and gender.   Information regarding the patients' pertinent medical history, current conditions, previous drug reactions or allergies and concomitant medications was not provided.  On 23-DEC-2024, the vaccines had a temperature excursion (time, temperature and prior excursions were unknown). On an unknown date, the patients were vaccinated with an improperly stored doses of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live recombinant Human albumin (rHA) (M-M-R II) injection (lot numbers Y013132 with expiration date: 30-JUL-2026 and X027903 with expiration date of 04-DEC-2025, both has been verified to be valid lot numbers for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live) administered for prophylaxis (strength, specific dosage, vaccination scheme, route of administration and anatomical site of application were not provided), with varicella virus vaccine live (Oka/Merck) (VARIVAX) injection (lot numbers Y010373 with expiration date:05-JUN-2026 and Y011712 with expiration date of 02-JUL-2026, both has been verified to be valid lot numbers for varicella virus vaccine live [Oka/Merck]) administered for prophylaxis (strength, specific dosage, vaccination scheme, route of administration and anatomical site of application were not provided) and with measles, mumps, rubella and varicella (oka-merck) virus vaccine live live recombinant Human albumin (rHA) (PROQUAD) injection (lot numbers Y013577 with expiration date: 03-FEB-2026 and Y016872 with expiration date of reported as 04-JUL-2026, but upon internal validation was stablished as 07-APR-2026, both has been verified to be valid lot numbers for measles, mumps, rubella and varicella (oka-merck) virus vaccine live) administered for prophylaxis (strength, specific dosage, vaccination scheme, route of administration and anatomical site of application were not provided) (product storage error).  This is a non-valid case due to the lack of patients' identifiers.  Follow-up information was received on 03-JAN-2025.   The patient's identifiers were provided, and they were a 5-year-old patient. The reporter stated that varicella virus vaccine live (Oka/Merck) (VARIVAX) was not administered, and only measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live recombinant Human albumin (rHA) (M-M-R II) and measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) were administered. The product of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live recombinant Human albumin (rHA) (M-M-R II) was stored in recommend range and no adverse event was being filed. On 30-DEC-2024, the patient was vaccinated with a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) injection lot # Y013580 and expiration date reported as and confirmed to be 03-FEB-2026 (temperature excursion [T/E]: current: 31-DEC-2024: 17.0F 1 hour 45 minutes 0 seconds; previous: 8.00F 0 hours 45 minutes and 12.0F 0 hours 50 minutes) (product storage error). No additional adverse event (AE) and no product quality complaint (PQC) was reported (no adverse event).